CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+18.21%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.42B
AUM Growth
+$1.42B
(+4.4%)
Cap. Flow
-$29.5M
Cap. Flow
% of AUM
-2.08%
Top 10 Holdings %
Top 10 Hldgs %
62.23%
Holding
38
New
7
Increased
10
Reduced
8
Closed
5
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$59.4M |
| 2 |
Cidara Therapeutics
CDTX
|
$57.2M |
| 3 |
Relay Therapeutics
RLAY
|
$46.2M |
| 4 |
Kymera Therapeutics
KYMR
|
$32.7M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$21.9M |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$62.3M |
| 2 |
Merus
MRUS
|
$49.9M |
| 3 |
Cogent Biosciences
COGT
|
$47.3M |
| 4 |
Soleno Therapeutics
SLNO
|
$45.2M |
| 5 |
Vera Therapeutics
VERA
|
$41.5M |
Sector Composition
| 1 | Healthcare | 99.44% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $185M | 13.09% |
3,525,000
-947,840
| -21% | -$49.9M |
|
2
Nuvalent
NUVL
$5.52B
| $105M | 7.41% |
1,375,000
-480,000
| -26% | -$36.6M |
|
|
3
Xenon Pharmaceuticals
XENE
$2.98B
| $94.7M | 6.68% |
3,025,000
+700,000
| +30% | +$21.9M |
|
4
Enliven Therapeutics
ELVN
$1.2B
| $94.1M | 6.64% |
4,692,809
+17,809
| +0.4% | +$357K |
|
5
Agios Pharmaceuticals
AGIO
$2.19B
| $77.3M | 5.46% |
2,325,000
+140,000
| +6% | +$4.66M |
|
6
Celldex Therapeutics
CLDX
$1.47B
| $70.2M | 4.96% |
3,450,000
+250,000
| +8% | +$5.09M |
|
7
Alkermes
ALKS
$4.78B
| $70.1M | 4.95% |
2,450,000
+500,000
| +26% | +$14.3M |
|
8
Viridian Therapeutics
VRDN
$1.5B
| $68.2M | 4.81% |
4,875,000
+1,275,000
| +35% | +$17.8M |
|
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $59.4M | 4.19% |
+1,075,000
| New | +$59.4M |
|
|
10
Cidara Therapeutics
CDTX
$1.66B
| $57.2M | 4.04% |
+1,175,000
| New | +$57.2M |
|
11
Scholar Rock
SRRK
$3.14B
| $51.4M | 3.63% |
1,450,000
-295,000
| -17% | -$10.4M |
|
|
12
Soleno Therapeutics
SLNO
$3.6B
| $51.1M | 3.61% |
610,000
-540,000
| -47% | -$45.2M |
|
|
13
Relay Therapeutics
RLAY
$619M
| $46.2M | 3.26% |
+13,350,000
| New | +$46.2M |
|
14
Nurix Therapeutics
NRIX
$714M
| $45M | 3.17% |
3,948,653
-30,254
| -0.8% | -$345K |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $43.3M | 3.06% |
3,298,289
+930,711
| +39% | +$12.2M |
|
16
Pharvaris
PHVS
$1.39B
| $33.6M | 2.37% |
1,911,433
| – | – |
|
|
17
Kymera Therapeutics
KYMR
$2.95B
| $32.7M | 2.31% |
+750,000
| New | +$32.7M |
|
18
MindMed
MNMD
$676M
| $32.5M | 2.29% |
5,000,000
+475,000
| +10% | +$3.08M |
|
19
Spyre Therapeutics
SYRE
$996M
| $29.8M | 2.1% |
1,988,084
| – | – |
|
20
Tyra Biosciences
TYRA
$675M
| $29.7M | 2.09% |
3,100,000
+2,150,000
| +226% | +$20.6M |
|
|
21
Vera Therapeutics
VERA
$1.38B
| $18.8M | 1.33% |
800,000
-1,761,782
| -69% | -$41.5M |
|
22
CytomX Therapeutics
CTMX
$336M
| $17.5M | 1.23% |
+7,692,300
| New | +$17.5M |
|
|
23
Cogent Biosciences
COGT
$1.69B
| $16.6M | 1.17% |
2,311,164
-6,581,652
| -74% | -$47.3M |
|
|
ORKA
24
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $15.9M | 1.12% |
1,419,714
| – | – |
|
|
DRUG
25
Bright Minds Biosciences
DRUG
$276M
| $13.1M | 0.92% |
500,000
| – | – |
|